PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma By Ogkologos - February 9, 2026 180 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PACT-21 CASSANDRA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Potential of Molecular Profiling to Refine Surgical and Radiotherapy Decision-Making in... September 4, 2024 New Blood Test Can Screen For Over 50 Cancers June 7, 2021 Intracranial Efficacy of Pembrolizumab in Patients with Brain Metastases June 20, 2023 Pediatricians’ Offices Can Help Parents Quit Smoking, Study Shows September 12, 2019 Load more HOT NEWS Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib... Over 600 people in England set to benefit from innovative lung... FDA Approves Pralsetinib for Lung Cancer with RET Gene Fusions EMA Recommends Extension of Therapeutic Indications for Rucaparib
